DeepWork Capital and GPG Ventures have invested in the US-based integrated digital health solutions company Recuro Health.

With the latest funding, Recuro has increased its total current investment to $22m.

Both financial sponsors have become part of the company’s existing investors from over-subscribed A-round, including ARCH Venture Partners, OLSF Ventures, Cortado Ventures, 1843 Capital and Sage Venture Partners.

The proceeds will be used by the company to boost its marketing and expanded capabilities in digital health.

Recuro Health CEO and founder Michael Gorton said: “The overwhelming response to Recuro in the financial community demonstrates market confidence in our leadership team, the growing range of innovative digital health solutions and the strides we are already making to bring more affordable, accessible healthcare to individuals nationwide.

“The relationships with DeepWork Capital and GPG further accelerate our growth and enable Recuro to better serve the needs of providers, payers and patients.”

The curated and integrated suite of digital solutions offered by Recuro are expected to address real market challenges.

Designed to meet the requirements of any population, Recuro’s fully customisable portfolio of solutions range from virtual primary care and behavioral telehealth to at-home testing and genetic screening.

The company offers a Covid-19 testing solution and is among the selected companies to collaborate directly with the US Department of Health and Human Services, the National Institute of Health and the FDA during the pandemic.

DeepWork Capital managing partner Benjamin Patz said: “Recuro is aligned with our goal to bring compelling investment opportunities to our limited partners.

“The exceptional executive leadership team is demonstrating the value of recognizing market opportunities and creating programs and services that answer pressing healthcare needs.

“Recuro is addressing many of the new, post-Covidpatient preferences for delivery of healthcare.”

In September this year, Recuro acquired an epigenetics platform MyLifeIQ to expand its suite of digital solutions.